Nurix director granted 31,250 stock options

Nurix Therapeutics, Inc. reported a Form 4 showing director Roger D. Dansey received a grant of stock options for 31,250 shares of common stock at an exercise price of $15.86 per share.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. reported a Form 4 showing director Roger D. Dansey received a grant of stock options for 31,250 shares of common stock at an exercise price of $15.86 per share. The option vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to continued service, and expires on May 14, 2036. This is a compensation-related award, not an open-market trade.

Insider Trade Summary

Grant/Award: 31,250 shares

Grant/Award 1 txn

Insider DANSEY ROGER D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	31,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 31,250 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Option grant size: 31,250 options Exercise price: $15.86 per share Underlying shares: 31,250 shares +2 more

5 metrics

Option grant size 31,250 options Director stock option award

Exercise price $15.86 per share Director stock option strike price

Underlying shares 31,250 shares Common stock underlying the option

Shares after transaction 31,250 derivative securities Total options held after this grant

Option expiration May 14, 2036 Director option expiry date

Key Terms

Director Stock Option (right to buy), exercise price, expiration date, vests as to 100% of the award, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 15.8600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-14T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests as to 100% of the award financial

"The stock option vests as to 100% of the award on the earlier"

annual meeting of the Issuer's stockholders financial

"on the earlier of (a) the date of the next annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nurix Therapeutics (NRIX) disclose for Roger D. Dansey?

Nurix disclosed a compensation-related grant of stock options to director Roger D. Dansey. He received options for 31,250 shares of common stock, recorded at a price of $0.00, reflecting an award rather than a market purchase.

How many Nurix Therapeutics (NRIX) shares are covered by Roger Dansey’s new option grant?

The option covers 31,250 shares of Nurix common stock. This entire amount represents newly granted derivative securities, giving the director the right to buy these shares if the options vest and are later exercised.

What is the exercise price of Roger Dansey’s Nurix (NRIX) stock options?

The options have an exercise price of $15.86 per share. This means Dansey can buy Nurix common stock at $15.86 if he chooses to exercise the option after it vests and before expiration.

When do Roger Dansey’s Nurix Therapeutics (NRIX) stock options vest?

The option vests as to 100% of the award on the earlier of the next annual meeting of stockholders or May 15, 2027. Vesting requires that Dansey remains in service to Nurix on the applicable vesting date.

When do Roger Dansey’s Nurix (NRIX) stock options expire?

The stock options expire on May 14, 2036. After this expiration date, Dansey can no longer exercise the option to purchase Nurix common shares at the $15.86 exercise price.

Did Roger Dansey buy or sell Nurix Therapeutics (NRIX) shares in the open market?

No open-market buy or sell occurred in this filing. The Form 4 reports a grant of stock options as compensation, with no shares purchased or sold on the market by Dansey in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DANSEY ROGER D

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.86	05/15/2026		A		31,250		(1)	05/14/2036	Common Stock	31,250	$0	31,250	D

Explanation of Responses:

1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Roger Dansey	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)